'''Aclarubicin''' ([[International Nonproprietary Name|INN]]) or '''aclacinomycin A'''<ref name="pubchem">{{PubChem|451415}}</ref> is an [[anthracycline]] drug<ref name="pmid1655244">{{cite journal |vauthors=Jensen PB, Jensen PS, Demant EJ |title=Antagonistic effect of aclarubicin on daunorubicin-induced cytotoxicity in human small cell lung cancer cells: relationship to DNA integrity and topoisomerase II |journal=Cancer Res. |volume=51 |issue=19 |pages=5093â€“9 |date=October 1991 |pmid=1655244 |doi= |url=http://cancerres.aacrjournals.org/cgi/pmidlookup?view=long&pmid=1655244|display-authors=etal}}</ref> that is used in the treatment of [[cancer]]. Soil bacteria ''[[Streptomyces galilaeus]]'' can produce aclarubicin. It can induce [[histone]] eviction from [[chromatin]] upon [[Intercalation (biochemistry)|intercalation]].<ref name="Pang">{{cite journal |vauthors=Pang B, Qiao X, Janssen L, Velds A, Groothuis T, Kerkhoven R, Nieuwland M, Ovaa H, Rottenberg S, van Tellingen O, Janssen J, Huijgens P, Zwart W, Neefjes J |title= Drug-induced histone eviction from open chromatin contributes to the chemotherapeutic effects of doxorubicin |journal= Nature Communications |volume=4 |pages=1908 |year=2013 |url=http://www.nature.com/ncomms/journal/v4/n5/full/ncomms2921.html |pmid= 23715267 |doi= 10.1038/ncomms2921 |pmc=3674280}}</ref><ref name="pang">{{cite journal |vauthors= Pang B, de Jong J, Qiao X, Wessels LF, Neefjes J |title= Chemical profiling of the genome with anti-cancer drugs defines target specificities |journal= Nature Chemical Biology |volume=11 |pages=472 |year=2015 |url=http://www.nature.com/nchembio/journal/v11/n7/full/nchembio.1811.html |pmid= 25961671 |doi=10.1038/nchembio.1811 |issue=7}}</ref>
